




Wednesday 31 October				
9:00am– 9:20am	<b>Welcome to AusBiotech 2018</b> QLD Government representative (TBA) <b>Glenn Cross</b> , Chief Executive Officer, AusBiotech			
9:20am– 10:00am	<b>Keeping the balance in your clinical portfolio - prioritization versus doing it all</b> <b>Dr Charmaine Gittleston</b> , Chief Medical Officer, CSL Limited			
10:00am– 10:30am	<b>Global life science investing &amp; industry update</b> <b>John Carroll</b> , Editor in Chief, Endpoints			
10:30am– 11:00am	Morning tea & networking with exhibitors in the exhibition hall			
11:00am– 12:30pm	<b>Precision medicines: maintaining competitiveness in the post-human genome project era</b> <i>This session will discuss the progression of precision medicines onto to the Australian market, implications for the industry &amp; strategies to help Australian companies maintain global competitiveness in the post-human genome project era</i> <b>Dr Lisette Pregeli</b> , UQ Post-doctoral Research Fellow, The University of Queensland Business School <b>Assoc Prof Damian Hine</b> , Strategy, The University of Queensland Business School	<b>The anatomy of a deal</b> <i>This session provides valuable insights from a spectrum of stakeholders with experience in developing complex deals with multinationals in licensing, providing a service or a product</i> <b>Dr Janette Dixon</b> , Chief Executive Officer/Principal, BioComm Pacific <b>Dr Andrew Kelly</b> , Executive Director, BioPacific Partners <b>Robert Sarrazin</b> , Vice President & Global Head of Search & Evaluation, GSK (invited) <b>Dr Birgit Reitmaier</b> , Head of Access to Innovation APAC, Merck	<b>Regenerative Medicine Stream</b> <b>A strategic view of the regenerative medicine landscape</b> <i>This session will aim to explore the scientific &amp; regulatory challenges related to progressing cell &amp; gene therapies, highlighting recent scientific, regulatory &amp; launch experience</i> <b>Chair: Dr Tim Oldham</b> , Executive Leader, Tijan Ventures <b>Dr Isabelle Riviere</b> , Director, Michael G. Harris Cell Therapy & Cell Engineering, Memorial Sloan Kettering Cancer Center (invited) <b>Dr Tim Farries</b> , Director of Regulatory Affairs for Cell & Gene	<b>Agriculture &amp; Agtech Stream</b> <b>Gene technologies</b> <i>'GMO' has been a disrupter in the way agriculture is produced but, with the advancement of gene editing technologies such as CRISPR, are GMOs now becoming redundant? New innovations in gene technologies &amp; nanotech &amp; current &amp; future application in agriculture</i> <b>Chair: Mike Pointon</b> , General Manager Innovation & Development, Nufarm Ltd <b>Prof Peter Waterhouse</b> , Professor of Molecular Genetics, Science & Engineering Faculty,








	<p><b>Ben Thorner</b>, Senior Vice President &amp; Head of Business Development &amp; Licensing, Merck Research Laboratories  <b>Kathy Connell</b>, Senior Director, New Ventures ANZ, Johnson &amp; Johnson Innovation  <b>Dr Anand Gautam</b>, Senior Director &amp; Head, External Science &amp; Innovation, Australia, New Zealand &amp; Southeast Asia, Pfizer</p>	<p><b>Craig Newton</b>, Chief Executive Officer, Vivazome  <b>Dr Paul Simmons</b>, Research &amp; New Product Development, Mesoblast</p> 	<p><b>Prof Guojie Zhang</b>, Associate Director, China National GeneBank, BGI  <b>Dr Nicole Jensen</b>, General Manager, Genetics &amp; Enabling Technologies, GRDC</p> <p><b>TropAg2019</b>  <small>International Tropical Agriculture Conference</small></p>	
<p>3:00pm– 3:30pm</p>	<p>Afternoon tea &amp; networking with exhibitors in the exhibition hall</p>			
<p>3:30pm– 5:00pm</p>	<p><b>New gene technology in diagnostics, vaccines &amp; CAR-T therapies</b>  <b>Dr Michelle Fraser</b>, CEO &amp; Managing Director, Reproductive Health Science Limited  <b>Dr Preethi Eldi</b>, Research Fellow School of Pharmacy &amp; Medical Sciences, UniSA  <b>Dr Janet Macpherson</b>, Development Manager, Cell &amp; Molecular Therapies, Royal Prince Alfred Hospital</p>	<p><b>Your company's first IND: getting to and through FDA</b>  <i>This session is aimed at helping small teams successfully prepare for the process of building &amp; submitting an IND &amp; to establish a productive, collaborative relationship with FDA</i>  <b>Chair:</b> Tba  <b>Evan Shave</b>, Associate Director, Global Tech Transfer, Process Engineering &amp; Validation, Patheon</p> 	<p><b>Regenerative Medicine Stream</b>  <b>Building regenerative medicine industries – international perspectives</b>  <i>An account of how different countries are advancing their regenerative medicine activities, in particular the government and regulatory settings to support regenerative medicine advances</i>  <b>Chair: Sue MacLeman</b>, CEO, MTPConnect Ltd  <b>Korea spotlight:</b>  <b>Dr So Ra Park</b>, Director of Global Stem Cell &amp; Regenerative Medicine Acceleration Centre (GSRAC)  <b>Japan spotlight:</b></p>	<p><b>Agriculture &amp; Agtech Stream</b>  <b>Food &amp; health</b>  <i>Recent achievements and future prospects in development &amp; deregulation of GM foods for improved human health</i>  <b>Chair: Dr Allan Green</b>, Innovation Leader, Agriculture &amp; Food, CSIRO  <b>Dr James Petrie</b>, Research Scientist, CSIRO  <b>Dist Prof James Dale</b>, Professor, Institute for Future Environments, Qld University of Technology  <b>Prof Mike Gidley</b>, Director, Centre for Nutrition &amp; Food Sciences, QAAFI, The University of Queensland</p>

			<p><b>Dr Fusako Nishigaki</b>, Vice Chair, Steering Committee, Forum for Innovative Regenerative Medicine (FIRM)</p> <p><b>Israel spotlight:</b>  <b>Dr Shir Mnuchin</b>, VP, Partnerships Connecting Industry, Academia &amp; Government, Bioforum Ltd.</p> <p><b>Canada spotlight:</b>  <b>Dr Michael May</b>, President &amp; Chief Executive Officer, CCRM</p> <p><b>Belgium spotlight:</b>  <b>Roland Gordon-Beresford</b>, Chief RA/IP Officer, Novadip Biosciences</p> 	<p><b>TropAg2019</b>  <small>International Tropical Agriculture Conference</small></p>
5:30pm–7:00pm	AusBiotech welcome reception in the exhibition hall			




**Thursday 1 November**

<p>9:00am– 9:45am</p>	<p><b>Millis Oration</b>  <b>Chair: Dr Andrea Douglas</b>, Vice President, R&amp;D Strategy &amp; External Affairs, CSL Limited  <i>The three pillars of WEHI's activities – science, translation &amp; entrepreneurship</i>  <b>Prof Doug Hilton</b>, Institute Director, Division Head of Molecular Medicine, Walter &amp; Eliza Hall Institute</p> 			
<p>9:45am– 10:30am</p>	<p><b>Immunology/Oncology – recent advances</b>  <b>Chair: Prof Rajiv Khanna</b>, Senior Scientist, QIMR Berghofer  <b>Panel:</b>  <b>Denis Patrick</b>, VP of External Innovation &amp; Science (oncology), Pfizer  <b>Dr Michael Rosenzweig</b>, Executive Director, Tumor Immunotherapy, Merck  <b>Dr Malcolm McColl</b>, Managing Director &amp; Chief Executive Officer, Viralytics (invited)</p> 	<p><b>Gender diversity in Australian biotech</b>  <i>#metoo - A closer look at women in leadership positions, exploring how Australia measures up in terms of women in senior roles, questioning the progress &amp; issues facing women in life sciences</i>  <b>Panel:</b>  <b>Sue Charles</b>, Managing Partner, Instinctif Partners  <b>Stuart Roberts</b>, Senior Analyst, NDF Research  <b>Samantha Cobb</b>, Chief Executive Officer, AdAlta  <b>Dr Amanda Gillon</b>, Investment Manager, Bioscience Managers  <b>Dr Krystal Evans</b>, Chief Executive Officer, BioMelbourne Network  <b>John Carroll</b>, Editor in Chief, Endpoints  <b>Diana Sternfeld</b>, Partner Fieldfisher</p>		
<p>10.30am– 11.00am</p>	<p>Morning tea &amp; networking with exhibitors in the exhibition hall</p>			
<p>11:00am– 12:30pm</p>	<p><b>Commercialising medicinal cannabis in Australia's evolving regulatory environment</b>  <i>Medical cannabis is legalised in many countries &amp; approved in Australia in late 2016. A number of medical conditions can be treated with cannabis extracts including chronic pain &amp; chemotherapy nausea. There is patient confusion &amp; frustration as the first companies navigate the complex regulatory environment &amp; gain medical</i></p>	<p><b>From bench to bedside: GPCR drug discovery</b>  <i>Despite significant market size, over 80% of GPCR targets are yet to be effectively exploited. This session will explore GPCRs in a number of therapeutic areas</i>  <b>Samantha Cobb</b>, Chief Executive Officer, AdAlta  <b>Assoc Prof Kevin Pflieger</b>, Chief Scientific Adviser, Dimerix Ltd  <b>Dr Chris Langmead</b>, Head, Servier Drug Discovery Program, Monash</p>	<p><b>Early stage investment</b>  <b>10 x 8min presentations</b>          Queensland ministerial speaker          TBA</p> 	<p><b>Clinical Trials Stream</b>  <b>Harness the power of data for smarter drug development</b>  <i>Today, clinical trials are accommodating an incredible variety of data &amp; content from various sources – from traditional clinical data, to high-resolution images, operational data &amp; much more. As clinical trials become more complex, the biggest challenge for stakeholders is to reduce study risk, meet complex regulatory</i></p>

	<p><i>acceptance through doctor education. This session will outline the opportunity &amp; progress in getting quality medical cannabis to Australian patient</i></p> <p><b>Dr Stewart Washer</b>, VP Business Development, Auscann  <b>Elaine Darby</b>, Chief Executive Officer, AusCann  <b>Peter Crock</b>, Chief Executive Officer, Cann Group  <b>Prof Cameron Scadding</b>, Executive Chairman, Source Certain International  <b>Matt Spitzer</b>, Program Coordinator, Oncology Clinical Trials, Mater Research</p>	<p>Institute of Pharmaceutical Services</p>		<p><i>requirements, &amp; reduce the life cycle of the clinical development without compromising the patient's experience</i></p> <p><b>Eunho Shin</b>, Head of Solution Consulting, Medidata Solutions</p> <p></p>
<p><b>12:30pm-1:30pm</b></p>	<p><b>Lunch &amp; networking with exhibitors in the exhibition hall</b></p>			
<p><b>1:30pm-3:00pm</b></p>	<p><b>Accelerating the path from bench to biotech: focusing on entrepreneurship to drive innovation</b></p> <p><i>The effect of building entrepreneurial capability in academic researchers has on transforming the innovation environment with a change in rate of research translation impact</i></p> <p><b>Dougal Edwards</b>, Chief Executive Officer, Bright Arena</p>	<p><b>The rise of Australian &amp; Chinese healthcare industries: regulation &amp; new technologies</b></p> <p><i>Outline of important regulatory changes in Australia &amp; China affecting manufacturers &amp; suppliers of pharmaceuticals &amp; medical devices that accompany rapid growth</i></p> <p><b>Chair: Kim O'Connell</b>, Partner, King &amp; Wood Mallesons  <b>Esther Hao</b>, Registered Foreign Lawyer, King &amp; Wood Mallesons</p>	<p><b>Early stage investment</b>  <b>10 x 8min presentations</b></p> <p></p>	<p><b>Clinical Trials Stream</b>  <b>Keys to winning clinical trial tenders in Australia</b></p> <p><i>Discussing how to attract sponsors from a Central Lab perspective, the importance of strategic partnerships &amp; attracting sponsors from a CRO perspective &amp; presenting on facing the issue of our global location &amp; turning it into a positive through planning (lane validation, packaging, transit times, infrastructure, population etc)</i></p>

	<p><b>Prof Darren Kelly</b>, Chief Executive Officer &amp; Managing Director, Occurx  <b>Dr Rob Grenfell</b>, Health Director, Health &amp; Biosecurity, CSIRO</p>	<p><b>Anna Feros</b>, Special Counsel, King &amp; Wood Mallesons  <b>Dr Mike Skalsky</b>, Senior Consultant, Emergo  <b>Brent Maxwell</b>, Amazon Web Services</p> 		<p><b>Panel:</b>  <b>Sonic</b> (invited)  <b>Linear</b> (invited)  <b>Brent McPherson</b>, National Business Development Manager, World Courier</p> 
<p>3:00pm – 3:30pm</p>	<p>Afternoon tea &amp; networking with exhibitors in the exhibition hall</p>			
<p>3:30pm – 5:00pm</p>	<p><b>Curing paralysis – what innovations do we need to accelerate delivery of an effective therapy</b>  <i>Repairing a paralysed spinal cord has long been considered impossible, but now innovative technologies are now making this a reality. This session will highlight the demands &amp; needs of the innovation pathway from patient through to advanced digital solutions</i>  <b>Chair: Assoc Prof James St John</b>, Head, Clem Jones Centre for Neurobiology &amp; Stem Cell Research, Griffith University  <b>Perry Cross</b>, Executive President, Perry Cross Spinal Research Foundation</p>	<p><b>The anatomy of a clinical trials claim</b>  <i>A claim made by a patient suffering serious injury in a clinical trial can have a significant impact on the business sponsoring the trial. In this session we shall walk through what happens when a clinical trial insurance policy is called upon to respond to a demand for compensation from an injured trial participant. Joining us will be three experts, an insurance company, an insurance broking house &amp; a legal firm</i>  <b>Chair: Estelle Smith</b>, Life Science Manager, Australia &amp; New Zealand, Chubb Insurance  <b>Panel:</b></p>	<p><b>Early stage investment</b>  <b>10 x 8min presentations</b></p> 	<p><b>Clinical Trials Stream</b>  <b>Niche (neurological) clinical trial capabilities in Australia</b>  <i>How we work with biotechnology companies to deliver their project</i>  <b>Dr Tina Soulis</b>, General Manager, Neuroscience Trials Australia  <b>Dr Andrew Evans</b>, Director of the Movement Disorders Service, Royal Melbourne Hospital  <b>Prof Mark Cook</b>, Chair of Medicine, St. Vincent's Hospital  <b>Dr Nick Opie</b>, Chief Technology Officer/Founder, Synchron Inc.  <b>Dr Rebecca Sheean</b>, Research Coordinator, Fight MND</p>



	<p><b>Dr Brent McMonagle</b>, ENT Surgeon, Gold Coast University Hospital</p> <p><b>Assoc Prof James St John</b>, Head, Clem Jones Centre for Neurobiology &amp; Stem Cell Research, Griffith University</p> <p><b>Genny Kroll-Rosen</b>, Clinical Operations Manager, Making Strides</p> <p><b>Prof David Lloyd</b>, Chair, Gold Coast Orthopaedics Research &amp; Education Alliance</p> 	<p><b>Scott Jordan</b>, Senior Claims Technical Specialist, Chubb Insurance</p> <p><b>Shane Aitken</b>, Chief Operating Officer, Avatar Insurance Brokers</p> <p><b>Karen Jones</b>, Partner, Wotton &amp; Kearney</p> 		
7:00pm – 11:00pm	Conference dinner at the Grand Chelsea Ballroom at the Mercure Brisbane Hotel			

Friday 2 November	
9:00am–10:00am	<p><b>Investor session</b></p> <p><b>Chair: Lawrence Gozlan</b>, Portfolio Manager, Scientia Capital</p> <p><b>Panel:</b></p> <p><b>John Carroll</b>, Editor in Chief, Endpoint</p> <p><b>James leong</b>, Head of IC – Chairman, Pagoda Investment</p>



10:00am– 10:30am	<b>Update on Innovation and Science Australia</b> <b>Dr Charlie Day</b> , Chief Executive Officer, Office of Innovation & Science Australia	
10:30am– 11:00am	<b>Morning tea &amp; networking with exhibitors in the exhibition hall</b>	
11:00am– 12:30pm	<b>Global life sciences outlook: leading in an era of unprecedented change</b> <i>Gain insights on the 2019 outlook for life sciences from pharmaceuticals &amp; biotechnology to diagnostics &amp; digital health with key highlights from geographic, technology, competitive &amp; customer perspectives</i> <b>Chair: Glenn Cross</b> , Chief Executive Officer AusBiotech <b>Rhenu Bhuller</b> , Partner & SVP, Transformational Health, Frost & Sullivan <b>Mark Dougan</b> , Consulting Director, Transformational Health, Frost & Sullivan  <div style="text-align: center;"> <p>F R O S T    S U L L I V A N</p> </div>	<b>Creating investor value – recent Australian public company exits</b> <b>Dr Malcolm McColl</b> , Chief Executive Officer, Viralytics (invited) <b>Rob Daniels</b> , Chief Executive Officer, Elastagen (invited)
12:30pm– 2:30pm	<b>Lunch, closing ceremony &amp; handover to AusBiotech 2019 in the exhibition hall</b>	